Creo Medical training programme to double Speedboat procedures says Proactive analyst

Proactive Research analyst Daniel Appiah presents his latest report on Creo Medical.

The company develops and sells surgical devices for minimally invasive endoscopic surgery, mainly to remove suspected early-stage bowel cancers and to expand cases of a narrowed oesophagus.

Creo recently said it expects to report a half year-on-half year increase in revenue of over 10% to around £13.5mln.

© 2022 Stockmark.it The Latest StockMarket News and Interviews